79 Quick summary: A significant study has revealed that over 15% of young Black women diagnosed with early-onset breast cancer carry specific genetic mutations, primarily within the BRCA1 and BRCA2 genes, which are strongly linked to highly aggressive triple negative tumours. These critical findings highlight major racial disparities in preventative screening access, as this demographic remains systematically less likely to be offered or to pursue crucial genetic testing due to systemic barriers, cost, and awareness. Reforming healthcare practice and public policy to guarantee equitable genetic screening is essential to enable early, life saving interventions, empower family members through cascade testing, and alleviate the profound psychological distress and well-being challenges associated with late stage cancer diagnoses. Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer, and new research has identified the genes most likely to be mutated and contributing to those risks. The study, published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, examined 686 young Black women diagnosed with invasive breast cancer at age 50 or younger in Florida and Tennessee between 2005 and 2018. Genetic testing found that 15.3% carried a gene variant with a suspected link to breast and/or ovarian cancer. Most mutations occurred in the BRCA1 and BRCA2 genes, with fewer in PALB2, ATM, and other genes. A family history of breast cancer was common among women with mutations in BRCA1, BRCA2, and PALB2. Triple-negative breast cancers, one of the most aggressive forms, were most often seen in women with BRCA1 mutations, and most of those women were diagnosed at or below age 40. For women with variants in other genes, age at diagnosis was more evenly distributed up to age 50. The findings point to the importance of genetic testing for young Black women, a group less likely to receive such screening compared with other racial and ethnic groups. “We must test at-risk women across all populations. Testing is essential to personalise treatment strategies and enable life-saving prevention for future cancers, and it may empower at-risk family members to get tested so they too can benefit from this information,” said senior author Tuya Pal, MD, of Vanderbilt University Medical Center. “Equitable access to inherited cancer testing ensures that all women, regardless of race, can benefit from precision medicine and take control of their genetic health.” Despite the clear benefits, disparities in genetic testing persist. Young Black women are less likely to be offered or to pursue testing due to factors including awareness, access, cost, and trust in healthcare systems. Testing not only informs treatment for the diagnosed individual but also enables cascade testing for relatives, allowing proactive steps such as increased screening or preventive options. BRCA1 and BRCA2 mutations are associated with significantly elevated lifetime risks of breast and ovarian cancers, often warranting enhanced surveillance such as annual MRI scans from a younger age or risk-reducing surgery. The concentration of BRCA1 mutations in women diagnosed at or below age 40 aligns with known patterns for the gene, which is linked to more aggressive triple-negative disease. This subtype lacks oestrogen, progesterone, and HER2 receptors, limiting targeted therapy options and often requiring chemotherapy. Family history emerged as a strong indicator for BRCA1, BRCA2, and PALB2 carriers, reinforcing the value of detailed pedigree analysis. However, reliance on family history alone may miss cases, as not all mutation carriers report affected relatives, supporting broader testing criteria for young Black women diagnosed with invasive breast cancer. Early-onset breast cancer represents a significant public health concern for Black women, who consistently show higher incidence of aggressive disease, compounded by socioeconomic factors and potential delays in diagnosis. Researchers stress that while genetics explain part of the disparity, environmental, lifestyle, and systemic factors also play a role. Health organisations, including the NHS, have expanded genetic testing pathways for breast cancer, though ensuring these services reach all communities equitably remains an ongoing priority. Integrating ancestry-informed risk assessment could help identify those who might benefit most from comprehensive panel testing beyond BRCA genes alone.